Combined hormonal contraception and COVID-19

Lete, Iñaki

doi:10.1080/13625187.2020.1867845

Cited by 13 publications

(6 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…COVID-19 causes a hypercoagulable state in some people, which may worsen the VTE risk associated with combined hormonal contraception, although the incidence of VTE in women of reproductive age with COVID-19 infection is unknown. Currently, there is no evidence to alter the use of estrogen containing contraceptive methods in individuals with mild or moderate COVID-19 infections [28]. As progestin-only contraception is not associated with an increased VTE risk, these methods are a preferred choice for infected individuals.…”

Section: Key Pointsmentioning

confidence: 99%

Effects of the COVID-19 pandemic on family planning services

Stanton

Bateson

2021

Current Opinion in Obstetrics &Amp; Gynecology

View full text Add to dashboard Cite

Purpose of review The COVID-19 pandemic has highlighted existing healthcare disparities worldwide and has challenged access to family planning (FP) services. Recent findings Research has identified ways in which government regulations and healthcare programs have inhibited or increased access to FP services, as well as how the pandemic has changed individuals’ sexual and reproductive health behaviors and intentions. Summary The pandemic has had both positive and negative effects on access to FP services. Innovations in various delivery services, extended use of contraception, telehealth for medication abortion, and a no-test medication abortion protocol have decreased the need for in-person visits and improved access to FP services.

show abstract

Section: Key Pointsmentioning

confidence: 99%

Effects of the COVID-19 pandemic on family planning services

Stanton

Bateson

2021

Current Opinion in Obstetrics &Amp; Gynecology

View full text Add to dashboard Cite

show abstract

“…In standard conditions of exposure to normal levels of sex hormones, the risk of thromboembolism is at least threefold higher in men than in women at any age, with a frequency that is higher in men during elderly age and lower in women throughout fertile age [ 120 ]. Female patients using hormonal contraception represent a risk category for venous thromboembolic disease [ 121 , 122 ], this being related to inappropriate activation of the coagulation cascade likely because of the pro-inflammatory cytokine storm induced by SARS-CoV-2 viral infection.…”

Section: Sex and Gender Factors In Covid-19-related Cvdsmentioning

confidence: 99%

Sex-Related Factors in Cardiovascular Complications Associated to COVID-19

et al. 2021

View full text Add to dashboard Cite

Coronavirus disease 2019 (COVID-19), the pandemic infection caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), presents with an extremely heterogeneous spectrum of symptoms and signs. The clinical manifestations seem to be correlated with disease severity. COVID-19 susceptibility and mortality show a significant sex imbalance, with men being more prone to infection and showing a higher rate of hospitalization and mortality compared to women. Such variability can be ascribed to both sex-related biological factors and gender-related behavioral cues. This review will discuss the potential mechanisms accounting for sex/gender influence in vulnerability to COVID-19. Cardiovascular diseases play a central role in determining COVID-19 outcome, whether they are pre-existent or arose upon infection. We will pay particular attention to the impact of sex and gender on cardiovascular manifestations related to COVID-19. Finally, we will discuss the sex-dependent variability in some biomarkers for the evaluation of COVID-19 infection and prognosis. The aim of this work is to highlight the significance of gendered medicine in setting up personalized programs for COVID-19 prevention, clinical evaluation and treatment.

show abstract

“…н., професор Камінський В.В. Ризик тромбоемболії, пов'язаний із COVID-19 Частота інфікування SARS-CoV-2 є нижчою серед жінок, і вони мають менш тяжкі симптоми та нижчий рівень смертності від COVID-19 [6]. Отримано дані, що смертність на 72% нижча у жінок репродуктивного віку та на 49,6% нижча у жінок в постменопаузі в порівнянні з чоловіками [7].…”

Section: обґрунтування узгодженої позиції передумовиunclassified

“…Стероїдні гормони є імуномодуляторами, які здатні впливати на імунну та запальну реакцію, спричинену COVID-19 [6]. 17β-естрадіол (Е 2 ) пригнічує вироблення прозапальних цитокінів (інтерлейкіну (ІЛ) типу 6, ІЛ-1β та фактору некрозу пухлини (ФНП) α), одночасно стимулюючи вироблення протизапальних цитокінів (ІЛ-4 та ІЛ-10) Т-лімфоцитами, та стимулює продукцію антитіл В-лімфоцитами [17].…”

Section: вплив естрогенів на імунну відповідьunclassified

“…На сьогодні немає доказів щодо впливу використання КГК, що містять естрадіолу валерат або 17β-естрадіол, у пацієнток із COVID-19. Відомо, що вплив контрацептивів, які містять естрадіол, на параметри згортання крові менший, ніж вплив КГК з етинілестрадіолом [6,23]. Протягом періоду між 7 травня та 15 червня 2020 р. дослідники з Королівського коледжу Лондона (King's College London) та компанії Zoe Global Limited (Лондон) збирали інформацію про використання гормональних препаратів і захворюваність на COVID-19 серед 1,6 млн жінок у Великій Британії за допомогою розробленого ними додатку (відстежувач симптомів COVID-19) [24].…”

Section: вплив естрогенів на імунну відповідьunclassified

See 1 more Smart Citation

On the use of sex steroids in women during the COVID-19 pandemic

Татарчук¹,

Дубоссарська

Pyrohova

et al. 2021

View full text Add to dashboard Cite

The document was approved at an expanded meeting of the Ukrainian Society of Gynecological Endocrinology with the involvement of all board members and representatives of the Association of Obstetricians-Gynecologists of Ukraine, the Association of Pharmacologists of Ukraine, the Association of Anesthesiologists of Ukraine, as well during the Third Ukrainian School of Gynecological and Reproductive Endocrinology with international participation ISGE 19–20.03.21.The COVID-19 pandemic has significantly impacted medical practice, in terms of organizational and clinical practices, posing a number of complex and contradictory challenges for professionals.This document is the result of the systematization of scientific data available by March 2021 and recommendations of international medical and specialized professional societies on controversial clinical issues in gynecological practice caused by the COVID-19 pandemic, as well as certain issues of safety and ratio of using hormonal drugs. The involvement of experts from professional associations of the obstetric and gynecological field, pharmacology, anesthesiology and vascular surgery and phlebology in the working group made it possible to formulate clinically justified provisions of the position.The position includes three thematic sections: “On the use of estrogen-containing combined hormonal contraceptives (CHC) during the COVID-19 pandemic”; “On the use of menopausal hormone therapy (MHT) during the COVID-19 pandemic”; “On the issue of unregistered compounded bioidentical hormones”. At the beginning of each thematic section, the main conclusions of the consensus position of professional medical associations are presented. According to the data available by March 2021, there is no reason to limit the use of CHC or MHT in healthy women (currently not having COVID-19). The question of CHC or MHT discontinuing or switching to other forms by women with COVID-19 should be decided depending on the severity of the disease, the total set of risk factors for thromboembolic complications and other individual characteristics of the clinical situation. Further research will provide elaboration of more detailed algorithms. Physicians need to be vigilant about the safety of compounded Bioidentical Hormonal Therapy (cBHT) in any dosage form (including pellets), especially during the COVID-19 pandemic, given the unexplored systemic effects and therefore the potential risks. Preference should be given to officially licensed medicinal products with a well-studied safety profile and clinical effects, the use of which is authorized by doctor's prescription and supported by clinical protocols and guidelines.

show abstract

Combined hormonal contraception and COVID-19

Cited by 13 publications

References 42 publications

Effects of the COVID-19 pandemic on family planning services

Effects of the COVID-19 pandemic on family planning services

Sex-Related Factors in Cardiovascular Complications Associated to COVID-19

On the use of sex steroids in women during the COVID-19 pandemic

Contact Info

Product

Resources

About